Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.

Authors

• Rebecca E Wrishko
• Jacqueline B McCrea
• Ka Lai Yee
• Wen Liu
• Deborah Panebianco
• Eric Mangin
• Manu Chakravarthy
• Maria P Martinez-Cantarin
• Walter K Kraft

Publication/Presentation Date

5-1-2019

Abstract

The original version of this article unfortunately contained a mistake.

Volume

39

Issue

5

First Page

453

Last Page

454

ISSN

1179-1918

Published In/Presented At

Wrishko, R. E., McCrea, J. B., Yee, K. L., Liu, W., Panebianco, D., Mangin, E., Chakravarthy, M., Martinez-Cantarin, M. P., & Kraft, W. K. (2019). Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects. Clinical drug investigation, 39(5), 453–454. https://doi.org/10.1007/s40261-019-00777-6

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

30895461

Department(s)

Administration and Leadership

Document Type

Article